Literature DB >> 15942877

The quinolones: past, present, and future.

Vincent T Andriole1.   

Abstract

The quinolone class of antimicrobial agents has generated considerable interest since its discovery >40 years ago. Substantial progress has been made in our understanding of the molecular mechanisms of the action of quinolones against pathogenic bacteria, the induction of resistance to quinolones in these organisms, and the potential of each quinolone compound to induce toxicity in treated patients. Here, these key discoveries are reviewed; the present indications approved by regulatory agencies are described in detail, with comments on adverse events caused by quinolones in treated patients; and speculation about the future of the quinolones is proffered, even though their future is difficult to predict, because many factors may affect their clinical usefulness. However, the emergence of bacterial resistance to the quinolones is a major factor that will determine the future clinical effectiveness of these agents, so that intense investigation of mechanisms to either prevent or curtail resistance to quinolones is of prime importance to their future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15942877     DOI: 10.1086/428051

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  75 in total

1.  Regional variations in quinolone use in France and associated factors.

Authors:  A Gallini; F Taboulet; R Bourrel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-29       Impact factor: 3.267

2.  Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.

Authors:  Katie J Aldred; Heidi A Schwanz; Gangqin Li; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  ACS Chem Biol       Date:  2013-09-30       Impact factor: 5.100

3.  Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.

Authors:  Elizabeth G Gibson; Alexandria A Oviatt; Monica Cacho; Keir C Neuman; Pan F Chan; Neil Osheroff
Journal:  Biochemistry       Date:  2019-10-28       Impact factor: 3.162

Review 4.  Antibiotic resistance mechanisms in M. tuberculosis: an update.

Authors:  Liem Nguyen
Journal:  Arch Toxicol       Date:  2016-05-09       Impact factor: 5.153

5.  Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.

Authors:  Yuri F van der Heijden; Fernanda Maruri; Amondrea Blackman; Ed Mitchel; Aihua Bian; Ayumi K Shintani; Svetlana Eden; Jon V Warkentin; Timothy R Sterling
Journal:  Int J Antimicrob Agents       Date:  2013-06-24       Impact factor: 5.283

6.  CIPROFLOXACIN RESISTANCE PATTERN AMONG BACTERIA ISOLATED FROM PATIENTS WITH COMMUNITY-ACQUIRED URINARY TRACT INFECTION.

Authors:  Ana Carolina Costa Reis; Susana Regia da Silva Santos; Siane Campos de Souza; Milena Góes Saldanha; Thassila Nogueira Pitanga; Ricardo Riccio Oliveira
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-07-11       Impact factor: 1.846

7.  Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions.

Authors:  Katie J Aldred; Heidi A Schwanz; Gangqin Li; Benjamin H Williamson; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  Biochemistry       Date:  2015-01-23       Impact factor: 3.162

8.  Analysis of two novel 1-4 quinolinone structures with bromine and nitrobenzyl ligands.

Authors:  Lidiane J Michelini; Wesley F Vaz; Giulio D C D'Oliveira; Caridad N Pérez; Hamilton B Napolitano
Journal:  J Mol Model       Date:  2019-02-08       Impact factor: 1.810

9.  Antibacterial properties of the CFTR potentiator ivacaftor.

Authors:  Leah R Reznikov; Mahmoud H Abou Alaiwa; Cassie L Dohrn; Nick D Gansemer; Daniel J Diekema; David A Stoltz; Michael J Welsh
Journal:  J Cyst Fibros       Date:  2014-03-05       Impact factor: 5.482

10.  Interplay in the selection of fluoroquinolone resistance and bacterial fitness.

Authors:  Linda L Marcusson; Niels Frimodt-Møller; Diarmaid Hughes
Journal:  PLoS Pathog       Date:  2009-08-07       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.